Providence, RI, July 2, 2013 – (eTeligis via Accesswire) – Mnemosyne Pharmaceuticals, Inc., an emerging biotechnology company focused on the discovery and development of small molecule drugs ...

Mnemosyne Pharmaceuticals Inc., an emerging biotech targeting central nervous system (CNS) disorders, raised $5.4 million in a Series A financing to advance its work on a class of molecules known as ...

Mnemosyne Pharmaceuticals, Inc. Completes $5.4 Million Series A Round to Support Drug Discovery Programs PROVIDENCE, RI, Feb 16, 2012 (MARKETWIRE via COMTEX) -- Mnemosyne Pharmaceuticals, Inc., an ...

Mnemosyne Pharmaceuticals Inc. has raised a $5.4 million Series A round to continue research on an oral drug with potential to treat cognitive symptoms of diseases such as schizophrenia and ...

Mnemosyne Pharmaceuticals Inc. has landed $5.4 million in a Series A funding round, led by Access BridgeGap Ventures of Cambridge, with participation from Slater Technology Fund, the official ...

Path to Mnemosyne will launch for PlayStation 4 and Switch on April 16 (April 17 for PlayStation 4 in Europe) for $9.99 / €9.99, publisher Hidden Trap and developer Devlish Games announced.